This discussion focused on the ways in which economic issues and industry characteristics interact with ongoing trends and new developments in life sciences antitrust. Panelists offered economic, legal, and industry perspectives on both new issues and perennial topics, including patent litigation settlements, acquisitions, and market concentration in health care and life sciences.

Panelists

Matthew Grennan

Associate Professor of Economic Analysis and Policy, and Faculty Co-director, Robinson Life Science, Business, and Entrepreneurship Program, Haas School of Business at the University of California, Berkeley